On 12 July, EIP Pharma Inc., which develops CNS-focused therapeutic drugs for improved patient benefit, announced the initiation of a new Phase II proof-of-concept trial evaluating neflamapimod in people with dementia with Lewy Bodies. Neflamapimod is an oral brain-penetrant molecule that inhibits the protein kinase p38 alpha, a kinase suggested to lead to the dysfunction of synapses that causes cognitive function deficits related to several neurodegenerative diseases.
The AscenD-LB Phase II study is a multi-centre, randomised, double-blind and placebo-controlled trial evaluating the effect of neflamapimod as a treatment for the cognitive dysfunction associated with dementia with Lewy bodies. The company is aiming to recruit around 80 participants in the US and Netherlands who will receive neflamapimod or placebo with food for 16 weeks. Data are expected in the second half of 2020.
